Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31385569 | 1.00 | CA12 (0.55) | CA12CA9KMT2AMEN1ALDH1A1 | |
| SCHEMBL19552318 | 0.84 | CA12 (0.49) | CA12CA9KMT2AMEN1ALDH1A1 | |
| SCHEMBL30881325 | 0.83 | CA12 (0.51) | CA12CA9KMT2AMEN1ALDH1A1 | |
| SCHEMBL30881314 | 0.80 | SMN1; SMN2 (0.50) | CA12CA9KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL17942059 | 0.79 | CA12 (0.56) | CA12CA9KMT2AMEN1ALDH1A1 | |
| SCHEMBL6151169 | 0.79 | CA12 (0.43) | CA12CA9KMT2AMEN1ALDH1A1 | |
| SCHEMBL22939448 | 0.79 | CA12 (0.48) | CA12CA9ALDH1A1 | |
| SCHEMBL28655810 | 0.79 | CA12 (0.55) | CA12CA9KMT2AMEN1ALDH1A1 | |
| SCHEMBL292179 | 0.76 | CA12 (0.47) | CA12CA9KMT2AMEN1ALDH1A1 | |
| SCHEMBL30881298 | 0.76 | CA12 (0.47) | CA12CA9KMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121800707-A | Preparation method of 3-phthalimido-2, 2-difluoropropionic acid | 海门瑞一医药科技有限公司 | 2026-04-07 | — | — | CN | disclosed |
| US-20190142804-A1 | FLUOROALKYL-SUBSTITUTED ARYLTRIAZOLE DERIVATIVES AND USES THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-05-16 | — | — | US | disclosed |
| US-20190142804-A1 | FLUOROALKYL-SUBSTITUTED ARYLTRIAZOLE DERIVATIVES AND USES THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-05-16 | — | — | US | disclosed |
| EP-3452469-A1 | FLUOROALKYL-SUBSTITUTED ARYLTRIAZOLE DERIVATIVES AND USES THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2019-03-13 | — | — | EP | disclosed |
| WO-2017191112-A1 | FLUOROALKYL-SUBSTITUTED ARYLTRIAZOLE DERIVATIVES AND USES THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-11-09 | — | — | WO | disclosed |
| WO-2017191112-A1 | FLUOROALKYL-SUBSTITUTED ARYLTRIAZOLE DERIVATIVES AND USES THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-11-09 | — | — | WO | disclosed |
| EP-2321319-B1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2012-03-14 | — | — | EP | disclosed |
| EP-2321319-B1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2012-03-14 | — | — | EP | disclosed |
| US-7998950-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998950-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998950-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| EP-2321319-A1 | ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010011959-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-01-28 | — | — | WO | disclosed |
| WO-2010011959-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-01-28 | — | — | WO | disclosed |
| US-20100022508-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| US-20100022508-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| US-20100022508-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022508-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | CA12 4309/4885CA9 3805/4885KMT2A 3803/4885 |
| US-20190142804-A1 | FLUOROALKYL-SUBSTITUTED ARYLTRIAZOLE DERIVATIVES AND USES THEREOF | AADAC, NAT1, FABP3 | CA12 4857/4885CA9 4342/4885KMT2A 2285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.